This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Eli Lilly, Ventyx Biosciences receive early termination from US FTC

( February 12, 2026, 17:29 GMT | Official Statement) -- MLex Summary: Eli Lilly and Co.'s acquisition of Ventyx Biosciences Inc. received approval in the US through an early termination by the US Federal Trade Commission, the agency announced. The companies received approval for their deal worth approximately $1.2 billion on Feb. 11, 12 days before the Hart-Scott-Rodino Act waiting period was set to expire on Feb. 23. The transaction was expected to close in the first half of 2026.See excerpt below....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login